Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • mudshark
    Senior Member
    • Jan 2009
    • 138

    #31
    Originally posted by captainentropy View Post
    @mudshark. You've tried quite a few programs. More than I have. Since I use QuEST the most could you tell me why you think it doesn't perform well? Did you use default or advanced parameter settings? This paper found most peak-calling programs to have high agreement between high-value peaks and qPCR verification data http://www.plosone.org/article/info:...l.pone.0011471
    based on my prior-knowledge system i can do a very good performance estimation of the tools. basically i know all the binding sites genome-wide without having to do ChIP mappings.

    of course, I am working in Drosophila and QuEST e.g. has been 'optimized' for mouse/human whatever that means. but in essence, QuEST has a very low sensitivity and given the low sensitivity a rather bad specificity COMPARED to other tools such as SICER, spp, and MACS.

    my experience.. other people might have a different one.

    (and of course i find QuEST very poorly documented - what are the advanced parameters?)

    Comment

    • captainentropy
      Member
      • Mar 2009
      • 89

      #32
      mudshark, if you include the "-advanced" option in the QuEST command you will have the option to configure all of the parameters such as bandwidth, region size, mappable genome fraction, ChIP enrichment, peak shift, etc. You can also control the peak collapsing parameters too.

      I recommend using the advanced option and at a minimum change the mappable genome fraction to something more accurate. The fraction is a function of the read length and percentage of mappable sequence (i.e. the non-repetitive sequences) for your genome. The longer the read length the larger the mappable fraction. The default in QuEST is 0.75 which (for hg18) corresponds to a readlength of 26nt. We are getting read lengths of 38nt and longer which increases the fraction to 0.82 and up. Using this number has resulted in a noticeable increase in number of peaks called.

      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Beyond CRISPR/Cas9: Understand, Choose, and Use the Right Genome Editing Tool
        by SEQadmin2



        CRISPR/Cas9 sparked the gene editing revolution for both research and therapeutics.1 But this system still showed severe issues that limited its applications. The most prominent were the heavy reliance on PAM sequences, delivery limitations, double-stranded breaks that prompt unintended edits and cell death, and editing inefficiency (both in targeting and in knock-in reliability).

        Despite this, “CRISPR helped turn genome editing from a specialized technique into
        ...
        07-31-2026, 11:01 AM
      • SEQadmin2
        Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
        by SEQadmin2


        Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

        The systematic characterization of the human proteome has
        ...
        07-20-2026, 11:48 AM
      • SEQadmin2
        Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
        by SEQadmin2



        Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
        ...
        07-09-2026, 11:10 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Yesterday, 10:13 AM
      0 responses
      14 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-31-2026, 02:55 AM
      0 responses
      29 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-24-2026, 12:17 PM
      0 responses
      21 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 07-23-2026, 11:41 AM
      0 responses
      21 views
      0 reactions
      Last Post SEQadmin2  
      Working...